PCRX Q4 2020 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$131M+7.0% YoY

Gross Profit

$96M73.1% margin

Operating Income

$19M14.3% margin

Net Income

$15M11.1% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$32M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$655M

Stockholders' Equity

$620M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$122M	+7.0%
Gross Profit	$96M	$91M	+5.7%
Operating Income	$19M	$2M	+995.8%
Net Income	$15M	-$5M	+397.0%

Revenue Segments

Product

$130M99%

Royalty

$1M1%